ELI LILLY AND COMPANY Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
ELI LILLY AND COMPANY (LLY) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $8.90 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2025-02-19
- ELI LILLY AND COMPANY unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $8.90M, a 58.60% decline from fiscal 2023.
- ELI LILLY AND COMPANY unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $21.50M, a 82.20% increase from fiscal 2022.
- ELI LILLY AND COMPANY unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $11.80M, a 76.26% decline from fiscal 2021.
- ELI LILLY AND COMPANY unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2021 was $49.70M, a 19.18% increase from fiscal 2020.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month as first filed |
|---|---|---|
| 2024-12-31 | $8.90M 10-K · filed 2025-02-19 | |
| 2023-12-31 | $21.50M 10-K · filed 2025-02-19 | |
| 2022-12-31 | $11.80M 10-K · filed 2025-02-19 | |
| 2021-12-31 | $49.70M 10-K · filed 2024-02-21 | |
| 2020-12-31 | $41.70M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $161.50M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $20.50M 10-K · filed 2021-02-17 | $23.50M 10-K · filed 2019-02-19 |
| 2017-12-31 | $19.30M 10-K · filed 2020-02-19 | |
| 2016-12-31 | $110.00M 8-K · filed 2019-10-24 | |
| 2015-12-31 | $4.00M 10-K · filed 2018-02-20 | |
| 2014-12-31 | $3.50M 10-K · filed 2017-02-21 | |
| 2013-12-31 | $24.90M 10-K · filed 2016-02-19 | |
| 2012-12-31 | $4.60M 10-K · filed 2015-02-19 | -$4.60M 10-K · filed 2013-02-21 |
| 2011-12-31 | $2.60M 10-K · filed 2014-02-19 | -$2.60M 10-K · filed 2012-02-24 |
| 2010-12-31 | -$7.00M 10-K · filed 2013-02-21 | |
| 2009-12-31 | -$3.30M 10-K · filed 2012-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |